Benzinga | Jan 21, 2022 09:04AM EST

Altamira Therapeutics Reports Approval Of Bentrio Nasal Spray In Malaysia

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics announced today that Bentrio(tm) has been approved by the Medical Device Authority of Malaysia and is, therefore, cleared for commercialization in that country.

The product will be commercialized through the local affiliate of Wellesta Holdings Pte Ltd, Singapore ("Wellesta"). Under a previously announced marketing and distribution agreement between the two companies, Wellesta will commercialize and distribute Bentrio(tm) in India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam. In addition to Malaysia, Bentrio(tm) has also received clearance in Singapore, and preparations and procedures for registration in the other countries are ongoing.

"We are very pleased with the swift 'go-to-market' progress in Malaysia and Singapore," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "Together with our partner, Wellesta, we look forward to making Bentrio available to consumers in these dynamic countries for the protection against airborne allergens and viruses. As previously indicated, we expect Bentrio sales in Asian markets to significantly contribute to our 2022 revenues."